Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

Article Hematology

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status

Gail J. Roboz et al.

BLOOD (2022)

Article Hematology

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Tim Grob et al.

Summary: Mutant TP53 AML and MDS-EB share similar molecular characteristics and survival outcomes, suggesting that they should be considered as distinct molecular disease entities.

BLOOD (2022)

Add to Collection

Article Biophysics

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

Daniel A. Pollyea et al.

Summary: The combination therapy of venetoclax and azacitidine has shown promising results in treating AML patients over 60 years old, with potential for improved outcomes compared to maintenance therapy. In particular, allogeneic stem cell transplant following ven/aza treatment in newly diagnosed AML patients shows excellent outcomes, suggesting the need for further investigation to refine timing and patient selection for transplant.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Hematology

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Alex Bataller et al.

Summary: The 2017 European LeukemiaNet guidelines for acute myeloid leukemia have been validated in a large cohort of patients and identified a genetic subset with a very poor prognosis.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

H. Moses Murdock et al.

Summary: Older patients with AML who undergo HCT have a high risk of relapse and poor survival. The outcomes of HCT in these patients are primarily driven by baseline genetic factors rather than mutations present in remission.

BLOOD (2022)

Add to Collection

Article Hematology

Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

Curtis A Lachowiez et al.

Lancet Haematology (2022)

Add to Collection

Article Hematology

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Andrew H. Matthews et al.

Summary: Using retrospective observational data, this study compared the outcomes of newly diagnosed AML patients receiving CPX-351 or ven/aza. The results showed no significant difference in overall survival between the two treatment methods. However, CPX-351 was associated with higher rates of infections, febrile neutropenia, and longer hospital stays.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Doehner et al.

Summary: The QUAZAR AML-001 trial evaluated the efficacy of oral azacitidine in patients with acute myeloid leukemia, showing improved relapse-free survival and overall survival, particularly in patients with NPM1(mut) and FLT3(mut).

BLOOD (2022)

Add to Collection

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Article Oncology

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Daniel Bottomly et al.

Summary: This report presents findings from a large cohort of AML patients, combining genomic, transcriptomic, and clinical data to uncover associations between drug sensitivity, cell differentiation state, and patient survival prediction.

CANCER CELL (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

Gautam Borthakur et al.

Summary: Fludarabine, cytarabine, GCSF (FLAG)-based induction/consolidation with gemtuzumab ozogamicin (FLAG-GO) achieves higher remission rates in core binding factor (CBF) acute myelogenous leukemia compared to FLAG-IDA. FLAG-GO regimen results in better clinical outcomes and deeper molecular clearance by qPCR assessment of fusion transcripts.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Meeting Abstract Hematology

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating

Daniel A. Pollyea et al.

BLOOD (2021)

Add to Collection

Article Oncology

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses

Alan K. Burnett et al.

Summary: The trial on the optimal treatment course for young AML patients showed that four courses were more effective in reducing relapse rate and improving relapse-free survival compared to three courses.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea et al.

Summary: The NCCN Guidelines for Acute Myeloid Leukemia provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment. Recent updates focus on familial genetic alterations, treatment strategies for low-risk and favorable-risk AML, venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Hematology

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl et al.

Summary: Combination therapy of venetoclax is effective in many patients with relapsed or refractory AML, with azacitidine+venetoclax showing higher response rates compared to low-dose cytarabine+venetoclax. Clinical and molecular characteristics of patients may predict treatment outcomes in this population.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

Evan M. Cherry et al.

Summary: Venetoclax plus azacitidine is the standard treatment for newly diagnosed AML patients who cannot undergo intensive chemotherapy. Patients eligible for intensive chemotherapy sometimes opt for ven/aza instead. In a retrospective analysis, patients receiving ven/aza had a higher response rate but shorter median overall survival compared to those receiving IC. Certain variables, such as age, AML subtype, and gene mutations, were identified that favored response to one treatment over the other.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Curtis A. Lachowiez et al.

Summary: This study compared outcomes in patients with spliceosome mutations vs wild-type patients treated with HMA+VEN regimens, revealing comparable responses and overall survival. Specific co-mutations, such as IDH2 and RAS, were found to impact outcomes in these patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome

Franziska Taube et al.

BLOOD (2021)

Add to Collection

Article Oncology

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo et al.

Summary: The combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with venetoclax showed to be an effective treatment regimen in both newly diagnosed and relapsed or refractory AML patients, resulting in deep remissions and high rates of successful transplantation.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology